Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Fluticasone propionate + salmeterol xinafoate by Korea United Pharm for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Fluticasone propionate + salmeterol xinafoate is under clinical development by Korea United Pharm and currently in Phase I for Chronic...